FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BIGHAM MICHAEL						2. Issuer Name and Ticker or Trading Symbol Paratek Pharmaceuticals, Inc. [PRTK]									S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)	`	(First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 02/02/2017										r (give title		Other (below)		
C/O PARATEK PHARMACEUTICALS, INC.															Chairman and CEO					
75 PARK PLAZA, 4TH FLOOR						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)														X Form filed by One Reporting Person						
BOSTON MA 02116														Form f	-	e tha	in One Rep	orting		
(City)	City) (State) (Zip)																			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day						Execution Date,			Transaction Dispos Code (Instr. and 5)		urities Acquired (A) sed Of (D) (Instr. 3,		Securit Benefic Owned		ties For cially (D)		rect (I)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amoun	ount (A) or (D)		e	Following (I Reported Transaction(s) (Instr. 3 and 4)		(Insi	tr. 4)	(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date,		4. Transaction Code (Instr. 8)		of E		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		of Der Sec	Price rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership	
					Code	v	(A)	(D)	Date Exercisable	Ex Da	piration te	Title	Amoun or Numbe of Shares							
Stock Option (right to buy)	\$15.1 ⁽¹⁾	02/02/2017			A		72,500		(2)	02	/01/2027	Common Stock	72,50		\$0	72,500		D		

Explanation of Responses:

- 1. The exercise price is equal to the closing sales price per share of Common Stock as reported on The Nasdaq Global Market on the date of grant.
- 2. The shares shall vest as to 1/36 of the shares on the one-month anniversary following February 2, 2017 and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service to the Company at each vesting date.

Remarks:

/s/ William M. Haskel, Attorney-in-Fact for Michael 02/06/2017 Bigham

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.